万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>风湿病学

ARTHRITIS & RHEUMATOLOGY《关节炎与风湿病》 (官网投稿)

简介
  • 期刊简称ARTHRITIS RHEUMATOL
  • 参考译名《关节炎与风湿病》
  • 核心类别 SCIE(2024版), 目次收录(维普),外文期刊,
  • IF影响因子
  • 自引率5.20%
  • 主要研究方向医学-RHEUMATOLOGY 风湿病学

主要研究方向:

等待设置主要研究方向
医学-RHEUMATOLOGY 风湿病学

ARTHRITIS & RHEUMATOLOGY《关节炎与风湿病》(月刊). Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://onlinelibrary.wiley.com/journal/23265205

3、投稿网址:https://mc.manuscriptcentral.com/ar

4、官网邮箱:artrheum@gmail.com(编辑部)

JDiamond@rheumatology.org(总编)

5、官网电话:919-650-1459, extension 205

6、期刊刊期:月刊,一年出版12期。

202184日星期三

                                 

 

投稿须知【官网信息】

 

Arthritis & Rheumatology

Author Guidelines

Manuscripts should be submitted online at:

http://mc.manuscriptcentral.com/ar

Editorial office contact information:

Arthritis & Rheumatology, Editor: Daniel H. Solomon, MD, MPH

Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

Editorial office: phone 919-650-1459, extension 205

E-mail: artrheum@gmail.com

Author Guidelines Table of Contents

Submission, format and organization

     Manuscript Types

     Clinical Trials

Video Abstracts

English-language editing service

Content, acronyms, and terminology

Statistical Reporting

Information on some specific study types

Compliance with research ethics standards

Illustrations

Graphic design assistance for schematic drawings

Tables

Supplementary material

Availability of data and deposition of select data sets in public repositories

References

Assignment of reviewers

Related manuscripts/Duplicate publication

Authorship criteria

Disclosure of interest

Copyright: Wiley Author Licensing Service

Author corrections on proofs

Page charge

Submission, format and organization

Submit all new manuscripts online, at http://mc.manuscriptcentral.com/ar. Check for an existing account. If you are submitting for the first time, create a new account. At the end of a successful submission, a confirmation screen with manuscript number will appear and you will receive an e-mail confirming that the manuscript has been received by the journal. If this does not happen, please check your submission and/or contact tech support at ts.mcsupport@thomson.com.

An electronic cover letter should accompany the manuscript. Note in the cover letter what type of manuscript (e.g., full-length article, brief report, concise communication, or letter to the editor); manuscripts should not be classified as editorials or special articles unless they have been specifically invited. Confirm that each individual named as an author meets the journal's criteria for authorship (listed in the Authorship Criteria section below).

Confirm in the cover letter that the manuscript has not been submitted or is not simultaneously being submitted elsewhere, is not at the time of submission under consideration by another journal or other publication, and that no portion of the data has been or will be published elsewhere while the manuscript is under review by the journal, unless rejected by Arthritis & Rheumatology or withdrawn by the author(s). If a manuscript is in “revision suggested” status with another journal, it is interpreted to be still under consideration by that journal; for the manuscript to be submitted to Arthritis & Rheumatology, it must first be officially withdrawn from consideration with the other journal. Similarly, a manuscript that is in “revision suggested” status with Arthritis & Rheumatology is deemed to be under consideration and may not be submitted to another journal unless the submission is withdrawn from Arthritis & Rheumatology.

Also confirm that no portion of the data has been or will be published elsewhere while the manuscript is under review by Arthritis & Rheumatology. Publication in proceedings or transactions of meetings or symposium volumes is considered to be prior publication that renders the manuscript ineligible. Currently publication on a preprint server also is considered by the journal to be prior publication. However, in the case of studies not involving clinical data, the authors are encouraged to contact the journal when advance submission to a preprint server is being considered, as exceptions may be granted. The publication of data in abstracts, and presentation in oral or poster sessions at meetings, do not constitute previous publication unless the abstract exceeds two pages in length and/or is cited in PubMed.

Indicate any financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work. Corresponding author should include address, telephone number, fax number, and e-mail address.

Type all pages of the manuscript, including those containing references, tables, and figure legends, double space in 12-point type, with 1-1½-inch margins. Number all sheets in succession, including references, tables, and figure legends. Title page is page 1. On the first page, type the running head (short title for top of each page), title (which cannot include any acronyms), names of the authors and their academic degrees, grants or other financial supporters of the study, address for correspondence and reprint requests, and corresponding author's telephone and fax numbers and e-mail address. Also on the first page, again indicate any financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work.

Manuscripts submitted to Arthritis & Rheumatology receive a preliminary quality review by the editorial staff and may be returned if length or formatting requirements are not met. All manuscripts are initially reviewed by members of the editorial board and a substantial proportion of manuscripts are returned without external review if judged to be not competitive or in line with the journal’s content range. Only a minority of submitted manuscripts achieve sufficient priority for acceptance, and editorial decisions balance assessments of research quality with considerations of novelty, translational impact (in the case of basic science studies), and interest for the journal’s broad readership. Given the competition for publication space, rebuttals to editorial decisions are not considered except in cases of a clear scientific error in the review.

Revised submissions must include a detailed response to the reviewers file that is uploaded in the Author’s Response section of the revision submission steps in ScholarOne. Please use this guide when creating your response file. We expect that the letter will include both responses to the reviewers' comments as well as text changes made in the paper, as opposed to just providing page locations where changes were made.

ORCID

Arthritis & Rheumatology requires the submitting author (only) to provide an ORCID iD when submitting a manuscript.

Manuscript Types

Authors are encouraged to consult the table Description of and Specifications for Each A&R Article Type for a summary of the key information provided below.

Full-length Articles and Brief Reports. Full-length articles are descriptions of original research that add to the body of knowledge in the rheumatic diseases. Brief reports are short papers on investigations into disease mechanisms, reports of clinical experience, therapeutic trials, or research and/or clinical contributions to diagnosis, treatment, etiopathology, and epidemiology of rheumatic diseases.

On the second page of full-length articles and brief reports, include an abstract of no more than 250 words. The abstract must be divided into the following sections: Objective, Methods, Results, and Conclusion. Authors should include numerical information in the Methods or Results sections of the abstract, such as sample sizes, numbers of specimens analyzed, and statistical significance (or confidence intervals) of the major findings.

Following this plan of organization and beginning on the third page, the following sections are standard: Introduction, Materials and Methods (or Patients and Methods), Results, Discussion, References, Figure Legends, and Tables. Subheadings may be included in the Materials and Methods (or Patients and Methods) section and the Results section, but not in the Introduction or Discussion sections. For all full-length articles and brief reports, including basic science and translational studies, authors are strongly encouraged to include in the Discussion a “limitations of the study" paragraph(s). This paragraph should begin with a statement along the lines of "The limitations of this study include... .”

The title should not overstate or overgeneralize from the findings of the study and should be worded in non-sentence form whenever possible (for instance, “Association of X With Y” as opposed to “X Is Associated With Y”).

Full-length articles should not exceed 4,200 words from Introduction through Discussion (i.e., not including references, tables, and figure legends). The total number of tables and figures combined may not exceed 6, and the number of references may not exceed 50 for full-length articles. Table titles and figure legends should be brief but allow the reader to understand the purpose of the table or figure at a glance. Figure legends should not exceed 200 words.

Brief reports should not exceed 2,500 words from Introduction through Discussion. The total number of tables and figures combined may not exceed 3, and the number of references may not exceed 15.

Case reports may no longer be submitted to the journal. In rare instances, brief reports that include case report information will be considered for publication. The main criterion for consideration will be that, in addition to the clinical description of a case or cases, the report includes investigative research that advances the field of rheumatology by, e.g., providing a key insight into disease mechanism. These should be submitted in brief report format, with an Introduction section, a Patients and Methods section (including, but not limited to, description of the case or cases), a Results section, and a Discussion section.

Reviews. Reviews are intended to critically analyze what is known regarding new and rapidly evolving fields. Reviews can focus on a basic/translational scientific issue, a clinical topic, or a new technology. Reviews are generally invited by the editors; however, unsolicited reviews will be considered. Reviews should include an abstract of no more than 250 words, presented in a single paragraph and not divided into sections (as required for full-length articles and brief reports). The text should begin with an Introduction and end with Conclusions. Organization of the text and content of other headings should be appropriate to the topic discussed. Reviews should not exceed 5,000 words from Introduction through Conclusions (i.e., not including references, tables, and figure legends). The total number of tables and figures combined may not exceed 6, and the number of references may not exceed 85. Captions of tables and figures should be brief but allow the reader to understand the purpose of the table or figure at a glance.

Expert Perspectives on Clinical Challenges. Expert Perspectives on Clinical Challenges presents an evidence-based perspective on a difficult clinical challenge (diagnostic, therapeutic, or otherwise) from a topic area expert. These manuscripts will primarily be invited by the editors; however, experts can propose topics through communicating directly with a member of the editorial board. The manuscript should not exceed 5,000 words from Clinical Challenge (see below) through Discussion (i.e., not including references, tables, and figure legends). The total number of tables and figures combined may not exceed 6, and the number of references may not exceed 85.

The manuscript should include the following sections. 1) Clinical Challenge: a succinct (1–3-sentence) description of the challenge being addressed. 2) Background: a broad framing of the challenge being addressed, including factors that cause it to be a challenge, the epidemiology of the clinical scenario, etc. 3) Approach: a description of the authors’ approach to the clinical challenge being addressed, augmented with one or more figures that describe the approach using a flow diagram (algorithm). The diagram should be drafted by the author, and will be redrawn by a graphic designer for consistency of style. In some cases several diagrams may be necessary to appropriately address patients at different phases of the illness or with different clinical characteristics. 4) Evidence: presentation of the best available evidence supporting the authors’ approach. Authors are not expected to conduct a full systematic literature review, but should compile the best and most relevant data to support their approach. An evidence table should be strongly considered. 5) Discussion: a relatively brief section addressing evidence gaps and how they can be filled to reduce uncertainty, any ongoing trials aimed at filling the evidence gaps, relevant pathophysiology or pharmacology, and/or other issues as appropriate.

Editorials. Editorials are succinct commentaries on a concurrently published article in Arthritis & Rheumatology. Editorials are invited by the editorial office, and should be submitted within 3 weeks of invitation. The word limit is 1,500, 1 table or figure is allowed, and the number of references may not exceed 15.

Notes From the Field. Notes From the Field are succinct commentaries on a current clinical, research, or policy issue in rheumatology. Many of these commentaries will be invited but authors are free to submit ideas to the Editor in Chief in the form of a one paragraph proposal. These commentaries are not vehicles to present primary evidence. They should aim for a broad rheumatology audience.  The word limit is 1,500, 1 table or figure is allowed, and the number of references may not exceed 15.

Letters to the Editor. The content of letters to the editor consist of one of the following. 1) Commentary on a previous article published in Arthritis & Rheumatology. The content of these letters should be closely focused on the content of the article being commented on. Letters that are commentaries on previous articles must be submitted within 6 months after print publication of the article. The authors of the article being commented on will be invited to submit a reply letter. Subsequent letters commenting on this reply letter will not be accepted. 2) Very short reports of original research findings, with no abstract or headings. 3) Commentary on an issue affecting rheumatology and the American College of Rheumatology.

Names of all authors of a letter to the editor should be included in the manuscript. For "reply" letters, it is not necessary that all authors of the article being commented upon be included as authors of the reply, particularly if the article had a large number of authors.

The length of letters to the editor should be no more than 500 words, including references.

Only 1 table or figure may accompany a letter to the editor, and the number of references may not exceed 10.

Clinical Images. Clinical images are photographic depictions—clinical, radiologic, or pathologic—of interesting rheumatologic phenomena. Images must be few in number (preferably only one), oriented horizontally, of high quality (minimum 300 dpi; 600 dpi preferred for microscopy images), and have a compelling appearance. They must be appropriately anonymized. Images that are simply a variation of illustrations appearing in standard textbooks of rheumatology will not be considered. The accompanying text must provide near certainty about the underlying diagnosis. Editors disfavor research-related images that do not yet have an accepted place in patient care. Text should be no more than 300 words, and the number of references may not exceed 3. Do not add separate figure legends to clinical images; the entire clinical image text is the figure legend. Images should be submitted in .tiff (preferred) or .eps format.

Video Abstracts

Arthritis & Rheumatology (A&R), Arthritis Care & Research (AC&R), and ACR Open Rheumatology (ACROR), now offer authors of accepted articles the opportunity to present their research visually through the use of video abstracts. A video abstract succinctly describes the purpose, methods, results, and relevance of a given study within approximately 3–5 minutes. These videos are intended for a medical/clinical audience of physicians and other health professionals, including those in general fields and specialties outside the practice and research of rheumatology.

Submission information

Video abstracts must be submitted during the manuscript revision process as a supplemental file.

Please do not try to upload a video abstract upon initial submission of your manuscript.

Videos should be submitted through the A&R/AC&R/ACRORScholarOne submission website as follows:

When submitting your revised manuscript, please indicate "yes" to the question, "Would you be interested in submitting a video abstract with your revised manuscript?"

Upload the video using the Video Abstract file designation.

Please note: video files too large to upload in ScholarOne may be alternately submitted as a URL for downloading (via a file transfer or cloud storage website, such as Dropbox). In these cases, include the URL link to the video file in a Word file using the Video Abstract file designation.

……

更多详情:

https://onlinelibrary.wiley.com/page/journal/23265205/homepage/forauthors.html


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭